Skip to main
OPT
OPT logo

Opthea (OPT) Stock Forecast & Price Target

Opthea (OPT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Opthea Ltd is focused on developing innovative biologic therapies for eye diseases, particularly through its lead product, OPT-302, which targets Vascular Endothelial Growth Factors C and D. Positive results from its Phase 3 COAST trial, anticipating improvements in best-corrected visual acuity (BCVA) of 3 to 5 letters, suggest strong potential for adoption among retinal specialists and broad coverage from payers. The company's early trial data indicates meaningful advancements in visual acuity compared to standard therapies, supporting a favorable outlook for future commercial success.

Bears say

Opthea Ltd reported a substantial net loss of $131.9 million, equating to $0.11 per share for the first half of FY 2025, indicating significant challenges in achieving financial viability. The company faces considerable risks that could impair its ability to reach peak commercial revenue estimates for its investigational product, OPT-302, largely influenced by market size, penetration rates, and pricing strategies. Furthermore, potential difficulties in securing necessary capital resources and ongoing challenges in program development and commercialization further contribute to a negative outlook for the company's financial stability.

Opthea (OPT) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opthea and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opthea (OPT) Forecast

Analysts have given Opthea (OPT) a Buy based on their latest research and market trends.

According to 8 analysts, Opthea (OPT) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opthea (OPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.